Zhang Zhi-Hui, Han Yun-Wei, Liang Hui, Wang Le-Min
Department of Thoracic Surgery, Affiliated Hospital of Tai'an Medical University, Tai'an, Shandong, 271000, China.
Department of Oncology, The First Affiliated Hospital of Sichuan Medical University, No. 25 Taiping Street, Luzhou, Sichuan, 646000, China.
Cancer Med. 2015 Nov;4(11):1633-8. doi: 10.1002/cam4.493. Epub 2015 Sep 2.
The aim of the study was to assess the clinical prognostic value of serum cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) for non-small-cell lung cancer (NSCLC) patients. Literatures related to effects of serum CYFRA21-1 and CEA on the prognosis of lung cancer patients were retrieved from databases such as PubMed, Springer Link, Embase, Wanfang, and CNKI. Meta-analysis was carried out using RevMan 5.1 software. Ten literatures involving 1990 NSCLC patients were selected in this study. Total survive estimation merging hazard ratio (HR) in all NSCLC patients with high-level serum CYFRA21-1 was 1.64 (95% CI 1.46-1.84, P < 0.001) and that in all NSCLC patients with high level serum CEA was 1.46 (95% CI 1.28-1.65, P < 0.001). Serum CYFRA21-1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable.
本研究旨在评估血清细胞角蛋白19片段（CYFRA21-1）和癌胚抗原（CEA）对非小细胞肺癌（NSCLC）患者的临床预后价值。从PubMed、Springer Link、Embase、万方和知网等数据库中检索了有关血清CYFRA21-1和CEA对肺癌患者预后影响的文献。使用RevMan 5.1软件进行荟萃分析。本研究选取了10篇涉及1990例NSCLC患者的文献。所有血清CYFRA21-1水平高的NSCLC患者的总生存估计合并风险比（HR）为1.64（95%CI 1.46-1.84，P<0.001），所有血清CEA水平高的NSCLC患者的总生存估计合并风险比为1.46（95%CI 1.28-1.65，P<0.001）。血清CYFRA21-1和CEA可作为NSCLC患者的预后因素。联合检测这两个指标将更可靠。
